Company Overview - AIM ImmunoTech Inc. is a notable stock within the Medical sector, which consists of 932 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - AIM ImmunoTech Inc. has achieved a year-to-date return of approximately 14.2%, outperforming the average gain of 8.9% for Medical stocks [4] - The Zacks Consensus Estimate for AIM's full-year earnings has increased by 3.8% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Industry Context - AIM ImmunoTech Inc. is part of the Medical - Drugs industry, which includes 141 companies and currently ranks 81 in the Zacks Industry Rank. This industry has seen an average gain of 4.3% year-to-date, further highlighting AIM's superior performance [6] - In comparison, another stock in the Medical sector, Alzamend Neuro, Inc., has a year-to-date return of 28.6% and belongs to the Medical - Biomedical and Genetics industry, which ranks 107 and has gained 21.9% year-to-date [5][7]

Core Viewpoint - Massimo Group will showcase its new 2026 product lineup at AIM Expo, emphasizing its expansion into higher-value powersports vehicles and electric utility products [1][5]. Product Offerings - The 2026 Sentinel Series will feature fully enclosed HVAC UTVs, while the MVR HVAC Pro Series will include electric carts designed for various applications [2][3]. - The Sentinel Series aims to enhance Massimo's premium UTV offerings with factory-installed heating and air conditioning, while the MVR HVAC Pro Series targets markets such as golf, NEV, municipal, security, and commercial uses [3]. Market Reception - The company has received strong early market feedback and pre-order interest for both the Sentinel Series and MVR HVAC Pro Series, which is expected to bolster dealer confidence ahead of the 2026 model year [3]. Dealer Engagement - AIM Expo serves as a platform for Massimo to connect with its dealer network and introduce new products, reflecting the company's focus on higher-value offerings that benefit both dealers and end-users [4]. - New dealer programs for 2026 will be presented, aimed at enhancing dealer profitability and long-term partnerships, including improved parts and service support, a dealer demo unit program, and rebate programs [4]. Industry Context - AIM Expo 2026 will gather various stakeholders from the powersports ecosystem, providing an opportunity for Massimo to showcase its 2026 lineup and dealer strategy [5].

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) is up 39% at $22.80 [3] - Rubico Inc. (RUBI) has increased by 21% to $1.30 [3] - Aimei Health Technology Co., Ltd (AFJK) is up 19% at $76.80 [3] - Sable Offshore Corp. (SOC) has risen 19% to $10.81 [3] - Diginex Limited (DGNX) is up 18% at $4.95 [3] - Sidus Space, Inc. (SIDU) has increased by 18% to $3.71 [3] - SELLAS Life Sciences Group, Inc. (SLS) is up 16% at $4.40 [3] - Alchemy Investments Acquisition Corp 1 (ALCY) has risen 14% to $16.24 [3] - Greenidge Generation Holdings Inc. (GREE) is up 11% at $1.65 [3] - Enigmatig Limited (EGG) has increased by 5% to $5.52 [3] Group 2: Premarket Losers - Intelligent Bio Solutions Inc. (INBS) is down 11% at $8.48 [4] - ZW Data Action Technologies Inc. (CNET) has decreased by 11% to $1.20 [4] - Nuvve Holding Corp. (NVVE) is down 9% at $2.31 [4] - ESH Acquisition Corp. (ESHA) has fallen 8% to $17.59 [4] - LZ Technology Holdings Limited (LZMH) is down 6% at $1.55 [4] - Oriental Rise Holdings Limited (ORIS) has decreased by 4% to $1.43 [4] - Cango Inc. (CANG) is down 3% at $1.45 [4] - Massimo Group (MAMO) has fallen 2% to $3.90 [4] - Anghami Inc. (ANGH) is down 2% at $3.68 [4] - AIM ImmunoTech Inc. (AIM) has decreased by 2% to $1.10 [4]

Core Viewpoint - AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 shares of outstanding common stock and for every outstanding option or warrant that has a right to receive stock dividends, with the record date set for January 9, 2026, and distribution on January 13, 2026 [1]. Group 1: Stock Dividend Details - The stock dividend will be issued to stockholders and holders of Alternate Securities, with fractional shares rounded down and cash distributed for any remaining fractions based on a share price of $1.305, the average price on December 29, 2025 [2]. - Stockholders will not need to take any action to receive the stock dividend, as their accounts will be credited automatically, and brokers will receive the additional shares on behalf of stockholders [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod), a first-in-class investigational drug [4].

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. 333-____________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Name, address, including zip code, and tele ...

Core Point - The Aviation Institute of Maintenance (AIM) will be the first aircraft maintenance trade school featured on Season 16 of Amazon Prime Video's The College Tour, indicating a significant milestone for the institution and the growing interest in aviation maintenance careers and skilled trades education [1] Group 1 - AIM's filming will commence on December 8, 2025, at its Hasbrouck Heights campus, showcasing the school's commitment to promoting aviation maintenance education [1] - The feature on a popular streaming platform reflects the increasing national momentum behind careers in aviation maintenance and skilled trades [1]

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Lead Asset**: Ampligen, a drug with potential in immuno-oncology, effective as both a monotherapy and a synergistic enhancer to checkpoint inhibitors across various solid tumors [8][12] Core Points and Arguments - **Ampligen's Potential**: - Demonstrated strong impact in improving response rates for patients who are refractory to checkpoint inhibitors [8] - Alters tumor microenvironment to enhance visibility to immune system, transforming "cold tumors" into "hot tumors" [11][12] - **Strategic Focus on Pancreatic Cancer**: - AIM has prioritized pancreatic cancer as its lead indication due to the high unmet medical need and potential for significant impact on patient survival [13][15] - The company aims to leverage its data showing Ampligen's ability to extend overall survival in pancreatic cancer, both as a monotherapy and in combination with AstraZeneca's Durvalumab [15][19] - Orphan drug designations received in the U.S. and Europe provide market exclusivity, enhancing the business opportunity [16][17] - **Market Context**: - Over 500,000 deaths annually from pancreatic cancer, with a low survival rate, highlighting the critical need for effective treatments [19] - The oncology sector is where significant biotech deals occur, with potential for billion-dollar partnerships [14][28] - **Clinical and Regulatory Strategy**: - AIM is working towards initiating a Phase 3 trial in pancreatic cancer, ideally in conjunction with checkpoint inhibitors [24][25] - The company has treated 57 subjects, demonstrating the ability to extend overall survival beyond standard care [25] - **Upcoming Milestones**: - Anticipation of a positive year-end report, which is expected to be a significant inflection point for the company [28] - Plans to find a big pharma partner to support the Phase 3 trial and capitalize on the research and development efforts [26][28] Other Important Content - **Collaborations**: - Successful collaborations with Merck and AstraZeneca have been crucial for advancing Ampligen's development [30] - Data from independent research institutions supports the efficacy of Ampligen in various cancers, not limited to pancreatic cancer [29][30] - **Quality of Life Considerations**: - Ampligen is noted for improving the quality of life for patients undergoing treatment, which is particularly important for those facing severe malignancies [15][16] - **Company's Position**: - AIM is a small biotech company with limited resources but is making significant strides in oncology research [31] - The CEO expressed gratitude towards collaborators, investors, and the research community for their support [39][40] This summary encapsulates the key insights from the AIM ImmunoTech conference, focusing on the company's strategic direction, clinical developments, and market opportunities in the context of pancreatic cancer and broader oncology applications.

Core Viewpoint - AI-Media has launched a comprehensive ADA Title II compliance program to assist U.S. state and local governments in meeting the latest federal digital accessibility requirements [1][2]. Group 1: Compliance Program Details - The ADA Title II Web and Mobile Accessibility Rule requires all digital services of public entities to comply with WCAG 2.1 AA standards, with compliance deadlines set for April 24, 2026, for entities serving over 50,000 people, and April 26, 2027, for smaller jurisdictions [1]. - AI-Media's compliance initiative includes a multi-month educational campaign providing practical tools and promoting solutions to streamline the compliance process [1][2]. Group 2: Technology and Solutions - AI-Media emphasizes two flagship technologies, LEXI Text and LEXI AD, which are AI-driven solutions for real-time captioning and audio description, crucial for achieving ADA compliance [2][3]. - The company has released a checklist of ten key points for ADA compliance, aligning with its Government Solutions program to support public entities with scalable technology and predictable cost models [2]. Group 3: Upcoming Events - AI-Media will host a national webinar on January 20, 2026, titled "ADA Title II - Achieving Compliance with Ease through AI," focusing on the accessibility requirements outlined in WCAG 2.1 AA standards [3]. Group 4: Company Overview - AI-Media (ASX: AIM) is a global leader in AI-driven speech translation, captioning, and language orchestration, providing reliable services that enhance communication efficiency and modern workflows [4].